SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

Employees

7,689

Sector

Pharmaceuticals

Calendar

10-23 - Q3 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-06-20	15.93 ¥	+0.19%	3,215,844
25-06-19	15.90 ¥	-0.75%	3,882,391
25-06-18	16.02 ¥	-1.72%	4,014,820
25-06-17	16.30 ¥	-0.67%	4,821,166
25-06-16	16.41 ¥	-0.85%	4,618,317

End-of-day quote Shanghai S.E., June 19, 2025

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2025-06-20			5-day change	1st Jan Change
15.93 ^CNY	+0.19%		-3.75%	+0.82%

06-11	Shandong Buchang Pharmaceuticals Gets Marketing Approval for Arthritis, Psoriasis Drug	MT
06-04	Buchang Pharmaceuticals' Unit Withdraws Clinical Application for Rabies Vaccine	MT

Capitalization	16.85B 2.35B 2.04B 1.92B 1.75B 3.23B 203B 3.64B 22.73B 8.71B 93.3B 8.81B 8.62B 343B	P/E ratio 2023	59x	P/E ratio 2024	-30.9x
Enterprise value	19.35B 2.7B 2.34B 2.21B 2.01B 3.7B 233B 4.18B 26.09B 9.99B 107B 10.11B 9.9B 394B	EV / Sales 2023	1.59x	EV / Sales 2024	1.76x
Free-Float	41.28%	Yield 2023	0.74%	Yield 2024	-

Shandong Buchang Pharmaceuticals Gets Marketing Approval for Arthritis, Psoriasis Drug	06-11	MT
Buchang Pharmaceuticals' Unit Withdraws Clinical Application for Rabies Vaccine	06-04	MT
Workshops of Buchang Pharmaceuticals' Unit Passes GMP Standards	05-28	MT
Buchang Pharmaceuticals Amends Warehouse Addresses in License	05-28	MT
Buchang Pharmaceuticals' Unit Gets Registration Certificate for Besilate Atracurium Injection	05-28	MT
Shareholder to Offload Stake in Buchang Pharmaceuticals Unit	05-27	MT
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 27, 2024.	05-09	CI
Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback announced on December 27, 2024 has closed with of 6,620,630 shares, representing 0.62% for CNY 98.06 million.	05-08	CI
Buchang Pharma's Unit Gets Nod to Amend Manufacturing License	05-05	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-25	CI
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 27, 2024.	04-01	CI
Buchang Pharmaceuticals Gets Approval for Rabies Vaccine Clinical Trial	03-12	MT
Buchang Pharmaceuticals Gets Approval for Chickenpox Vaccine Clinical Trial	03-12	MT

1 day	+0.19%
1 week	-3.75%
Current month	-4.61%
1 month	-1.30%
3 months	+4.60%
6 months	-5.01%
Current year	+0.82%

Shandong Buchang Pharmaceuticals Co., Ltd. Stock

Equities

603858

CNE100002FV6

Pharmaceuticals

Valuation: Shandong Buchang Pharmaceuticals Co., Ltd.

Chart: Shandong Buchang Pharmaceuticals Co., Ltd.

Latest news: Shandong Buchang Pharmaceuticals Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shandong Buchang Pharmaceuticals Co., Ltd.

ETFs: Shandong Buchang Pharmaceuticals Co., Ltd.

Alternative Medicine

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	15.85	16.64
1 month	15.85	17.08
Current year	13.83	17.08
1 year	13.83	19.7
3 years	13.83	27.91
5 years	13.83	33.12
10 years	13.83	91.96

Manager	Title	Age	Since
Bao Cai Wang DFI	Director of Finance/CFO	61	2012-03-10
Chao Zhao PSD	President	58	2012-03-10
Xi Fang Wang CTO	Chief Tech/Sci/R&D Officer	66	2017-03-25

Director	Title	Age	Since
Tao Zhao CHM	Chairman	59	2012-03-10
Chao Zhao BRD	Director/Board Member	58	2012-03-10
Yi Min Wang BRD	Director/Board Member	63	2017-03-25

	2023	2024
Net sales	13.25B 1.85B 1.6B 1.51B 1.37B 2.53B 160B 2.86B 17.86B 6.84B 73.32B 6.92B 6.78B 270B	11.01B 1.53B 1.33B 1.26B 1.14B 2.11B 133B 2.38B 14.84B 5.69B 60.92B 5.75B 5.63B 224B
Net income	319M 44.44M 38.63M 36.41M 33.09M 61.05M 3.85B 68.9M 430M 165M 1.77B 167M 163M 6.49B	-554M -77.15M -67.07M -63.21M -57.45M -106M -6.68B -120M -747M -286M -3.07B -289M -283M -11.27B
Net Debt	2.25B 313M 272M 256M 233M 430M 27.09B 485M 3.03B 1.16B 12.44B 1.17B 1.15B 45.71B	2.49B 347M 302M 285M 259M 477M 30.07B 539M 3.36B 1.29B 13.8B 1.3B 1.28B 50.73B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.19%	-3.75%	+1.98%	-19.18%	2.35B
DONG-E-E-JIAO CO.,LTD.	+0.38%	-2.95%	-20.36%	+42.25%	4.68B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	-0.29%	-0.47%	-15.60%	-1.23%	3.52B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-0.07%	-4.20%	-12.41%	-42.21%	3.24B
TASLY PHARMACEUTICAL GROUP CO., LTD	+0.45%	-3.31%	+17.78%	+46.64%	3.23B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.52%	-3.43%	-4.42%	+34.96%	3.1B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-4.12%	-3.51%	-6.13%	+78.48%	1.79B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+1.91%	-6.98%	+13.20%	-14.28%	1.65B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	-0.06%	-2.55%	+12.08%	+84.91%	1.62B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	+0.27%	-3.67%	+17.63%	-45.47%	1.54B
Average	-0.19%	-2.70%	+0.38%	+16.49%	2.67B
Weighted average by Cap.	-0.12%	-2.41%	-3.16%	+17.04%